Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Sundise Reports Positive Results from TCM Liver Fibrosis Trial

publication date: Nov 7, 2013
Shanghai Sundise TCM Co. announced results from a US Phase II double-blinded, placebo-controlled clinical trial of a TCM product, Fuzheng Huayu tablet (FZHY). FZHY is used to treat liver fibrosis, and it was tested in chronic hepatitis C patients who have moderate to severe fibrosis. The drug was safe, well-tolerated and tended to stabilize or improve liver fibrosis, according to Sundise. To date, specific data from the trial has not been released. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital